Portfolio News

Cytox’s breakthrough polygenic risk scoring approach for assessing Alzheimer’s disease risk poised to accelerate therapeutic targeting. See BioCentury’s report on ‘Diagnosing AD Trials, Product Development March 6 2017. To view a copy of the report please download here.

read more

Perfectus Biomed will be exhibiting at SAWC Spring, April 5-9, 2017 in San Diego. The Symposium on Advanced Wound Care Spring | Wound Healing Society meeting is the largest gathering of multi-disciplinary wound care clinicians in the United States. SAWC … Continued The post SAWC Spring: Perfectus Biomed to Exhibit appeared first on Perfectus Biomed.

read more

CEO Ann Kramer will talk at the Angels in MedCity – Oxford Information Evening 28 March 2017, 17:00 –  20:00 Penningtons Manches Oxford, 9400 Garsington Road, Oxford Business Park, OX4 2HN MedCity in conjunction with Penningtons Manches would like to invite you to an information evening about the Angels in MedCity initiative. The event will... Read more »The post Angels in MedCity – Oxford Information evening – 28th March 2017 appeared first on The Electrospinning Company.

read more

Pioneering approach combines SNP panel with PRS algorithms for identifying true amyloid positive and true amyloid negative individuals in pre-symptomatic and MCI subjects 20 March 2017, Oxford, UK. Cytox Ltd, whose mission is to transform treatment decisions for Alzheimer’s disease (AD) by delivering clinically actionable information to assess risk and prediction of developing dementia, has...

read more

Perfectus Biomed are delighted to announce that they will appear in the SuperNorth Life Sciences Supplement which has been published today with The Times newspaper. On page 2 of SuperNorth, the achievements of the winners at the 15th Bionow Annual … Continued The post SuperNorth Supplement with The Times: Perfectus Biomed’s Bionow Achievement appeared first on Perfectus Biomed.

read more

1 2 3 5